Medtronic today announced the start of a prospective, observational, global, multicentre, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion thoracic stent graft system in the treatment of thoracic aortic dissection. The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York, USA by Derek Brinster, director of Aortic Surgery.
“Treatment of aortic dissection is often challenging, especially as patients with fragile aortas have different needs. The Valiant Navion CoveredSeal configuration, designed with fragile aortic tissue in mind, can be especially helpful in treating this condition,” said Ross Milner, director of the Center for Aortic Diseases at the University of Chicago Medicine in Chicago, USA and US principal investigator for the DISSECT-N study. “I believe the DISSECT-N study—one of the larger prospective aortic dissection repair studies, which includes independent core-lab imaging review—will offer critical contemporary insights about TEVAR use in patients with various types of thoracic aortic dissection.”
The DISSECT-N study will enrol at least 200 patients with an acute or chronic thoracic aortic dissection across approximately 45 sites in North America, Europe, and Asia Pacific. The primary endpoint is composite safety and effectiveness, including technical procedure success and freedom from major adverse events (MAEs) reported up to one month following the index procedure. Patients will be followed for three years. Primary investigators are Dr. Milner and Robin Heijmen, M.D., Ph.D., cardiothoracic surgeon at St. Antonius Hospital in the Netherlands.
“Thoracic aortic dissection is dangerous, with some cases leading to severe internal bleeding or irreversible organ damage; with the Valiant Navion system, more patients with aortic dissection are eligible for thoracic endovascular aneurysm repair (TEVAR),” said Robin Heijmen (St Antonius Hospital, Nieuwegein, the Netherlands), European principal investigator for the DISSECT-N study. “I am pleased to support the generation of real-world evidence in this landmark study, which I believe will help enable the clinical community to optimally treat patients with thoracic aortic dissection using this technology.”
“There remains a significant clinical unmet need in treating thoracic dissection, and we are dedicated to improving the care for these patients through an endovascular approach,” said John Farquhar, vice president and general manager of the Aortic business, which is part of the Cardiac and Vascular Group at Medtronic. “With the DISSECT-N study, we hope to further support the Valiant Navion system as a less invasive approach to treating this condition.”
The low-profile Valiant Navion system received US Food and Drug Administration approval in October 2018, CE mark in November 2018, and approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan in September 2019.